Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. My name is RJ, and I will be your conference operator today.
Xenon Pharmaceuticals Inc. (XENE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 5,424,444 | $243,123,580 | +1% | 2.39% |
| 2. | Driehaus Capital Richard Driehaus | 4,538,691 | $203,424,131 | +9% | 1.38% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,465,694 | $110,512,405 | -4% | 0.43% |
| 4. | Braidwell LP Alex Karnal | 1,825,076 | $81,799,906 | -50% | 2.62% |
| 5. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,800,000 | $80,676,000 | -34% | 5.37% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.81 | 700 | $20,167.00 | 700 | 2022-01-21 | Filing | |
| $24.40 | 4,000 | $97,600.00 | 4,000 | 2021-12-06 | Filing | |
| $2.22 | 15,000 | $33,280.50 | 44,210 | 2017-11-15 | Filing | |
| $2.95 | 8,000 | $23,600.00 | 29,210 | 2017-09-22 | Filing | |
| $2.95 | 2,000 | $5,900.00 | 21,210 | 2017-09-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.93 | 2,062 | $92,645.66 | 6,000 | 2026-01-02 | Filing | |
| $44.40 | 37,938 | $1,684,447.20 | 8,062 | 2026-01-02 | Filing | |
| $46.32 | 2,010 | $93,103.20 | 6,000 | 2025-12-08 | Filing | |
| $45.59 | 8,820 | $402,103.80 | 8,010 | 2025-12-08 | Filing | |
| $45.03 | 14,375 | $647,306.25 | 16,830 | 2025-12-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,920,250 | $399,805,605 | 0.02% | |
| 2. | 5,100,284 | $228,594,728 | 0% | |
| 3. | 4,764,779 | $213,557,396 | 0.04% | |
| 4. | 4,084,034 | $183,109,819 | 0.08% | |
| 5. | 3,414,959 | $153,058,462 | 0.02% |
News See All
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript August 11, 2025Xenon Pharmaceuticals Inc. misses on earnings expectations.
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript
Operator: Hello and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Xenon Pharmaceuticals, Inc. Earnings Conference Call.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Xenon Pharmaceuticals, Inc.
Hedge Fund Resource Center